BeyondSpring Files 2022 Annual Report on Form 20-F
18 Abril 2023 - 5:30PM
BeyondSpring Inc. (the “Company” or
“BeyondSpring”) (Nasdaq: BYSI), a clinical-stage global
biopharmaceutical company focused on using its novel technology
platform for drug discovery and development of innovative therapies
to improve clinical outcomes for patients with high unmet medical
needs, today announced that it has filed its annual report on Form
20-F for the fiscal year ended December 31, 2022 with the U.S.
Securities and Exchange Commission (“SEC”) on April 18, 2023. The
annual report on Form 20-F, which contains the Company’s audited
consolidated financial statements, can be accessed on the SEC’s
website at www.sec.gov and on the Company’s website at
www.beyondspringpharma.com under “Financials & Filings” in the
Investors section.
The Company will provide a hard copy of its annual
report containing its audited consolidated financial statements,
free of charge, to its shareholders upon request. Requests should
be directed to Investor Relations, BeyondSpring Inc., 28 Liberty
Street, 39th Floor, New York, NY 10005 USA.
About BeyondSpring Headquartered in New York
City, BeyondSpring is a clinical-stage global biopharmaceutical
company focused on using its novel technology platform for drug
discovery and development of innovative therapies to improve
clinical outcomes for patients with high unmet medical needs. Its
subsidiary SEED Therapeutics is leveraging a proprietary targeted
protein degradation drug discovery platform with an initial R&D
collaboration with Eli Lilly. Its first-in-class lead asset,
Plinabulin, is being developed as a potential “pipeline in a drug”
in various cancer indications as a direct anti-cancer agent and to
prevent chemotherapy-induced neutropenia (CIN). The Plinabulin and
G-CSF combination for the prevention of CIN has demonstrated
positive Phase 3 data in the PROTECTIVE-2 study. In the DUBLIN-3
study, a global, randomized, active controlled Phase 3 study, the
Plinabulin and docetaxel combination met the primary endpoint of
extending overall survival compared to docetaxel alone in
2nd/3rd line non-small cell lung cancer (NSCLC) (EGFR wild
type). Additionally, Plinabulin is being broadly studied in
combination with various immuno-oncology regimens that could boost
the efficacy of PD-1/PD-L1 antibodies in seven different cancers.
Lastly, BeyondSpring’s pipeline includes three preclinical
immuno-oncology assets and a subsidiary.
Cautionary Note Regarding Forward-Looking
StatementsThis press release includes forward-looking
statements that are not historical facts. Words such as “will,”
“expect,” “anticipate,” “plan,” “believe,” “design,” “may,”
“future,” “estimate,” “predict,” “objective,” “goal,” or variations
thereof and variations of such words and similar expressions are
intended to identify such forward-looking statements.
Forward-looking statements are based on BeyondSpring’s current
knowledge and its present beliefs and expectations regarding
possible future events and are subject to risks, uncertainties and
assumptions. Actual results and the timing of events could differ
materially from those anticipated in these forward-looking
statements as a result of several factors including, but not
limited to, our ability to continue as a going concern,
difficulties raising the anticipated amount needed to finance the
Company’s future operations on terms acceptable to the Company, if
at all, unexpected results of clinical trials, delays or denial in
regulatory approval process, results that do not meet the Company’s
expectations regarding the potential safety, the ultimate efficacy
or clinical utility of the Company’s product candidates, increased
competition in the market, the Company’s ability to meet Nasdaq's
continued listing requirements, and other risks described in
BeyondSpring’s most recent Form 20-F on file with the U.S.
Securities and Exchange Commission. All forward-looking statements
made herein speak only as of the date of this release and
BeyondSpring undertakes no obligation to update publicly such
forward-looking statements to reflect subsequent events or
circumstances, except as otherwise required by law.
Investor Contact:IR@beyondspringpharma.com
Media
Contact:PR@beyondspringpharma.com
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
BeyondSpring (NASDAQ:BYSI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024